Joel Jung and Peter Soparkar
Counsyl has appointed Joel Jung to serve as CFO and Peter Soparkar to serve as general counsel. Jung most recently served as CFO of BioNano Genomics, and previously served as CFO and treasurer of AgraQuest which was acquired by Bayer in 2012, and as CFO and treasurer for Celera. Soparkar joins Counsyl from Jazz Pharmaceuticals, and previously worked at Latham & Watkins in London and San Francisco.
Bernhard Kirschbaum and Oliver Schacht
Protagen has appointed Bernhard Kirschbaum as chairman of its supervisory board and Oliver Schacht as a new board member. Kirschbaum is a former Merck executive and has been a member of the Protagen board since 2015. He is taking over as the role of chairman from Axel Kleemann, who has served in the position for the past 15 years. Schacht successfully completed the IPO of Curetis last November, and has served in executive positions at Epigenomics in Seattle and in Berlin. He is currently a member of the executive board of BioDeutchland.
Biotheranostics has appointed Don Hardison to its board of directors. Most recently, he served as president, CEO, and director at Good Start Genetics. Hardison has more than 30 years of experience working for such companies as Exact Sciences, Laboratory Corporation of America, Quest Diagnostics, and SmithKline Beecham.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.